Drugs for Chronic Spontaneous Urticaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 67)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Omalizumab |
Approved, Investigational |
Phase 4 |
|
242138-07-4 |
|
Synonyms:
242138-07-4
D05251
Omalizumab
Omalizumab (genetical recombination)
|
Omalizumab (genetical recombination) (JAN)
Omalizumab (USAN/INN)
Xolair
Xolair (TN)
|
|
2 |
|
Benralizumab |
Approved, Investigational |
Phase 4 |
|
1044511-01-4 |
|
3 |
|
Loratadine |
Approved, Investigational |
Phase 4 |
|
79794-75-5 |
3957 |
Synonyms:
1-Piperidenecarboxylic acid, 4-(8-chloro-5,6-duhydro-11H-benzo [5,6]cyclohepta[1,2-b]-pyridin-11-ylidene)-, ethyl ester
1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester
1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester
1-piperidinecarboxylic acid,4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-,ethyl ester
4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester
4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester
4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester
4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester
79794-75-5
AC1L1H3E
AC-2086
Aerotina
Alarin
Alavert
Alavert, Claritin, Loratadine
Alerpriv
Allertidin
Amantadine
Anhissen
BB_SC-2109
Bedix Loratadina
BIDD:GT0198
Biloina
Bonalerg
BRD-K82795137-001-02-3
BRD-K82795137-001-10-6
BSPBio_002300
C22H23ClN2O2
CHEMBL998
Children's Claritin
CID3957
Civeran
Claratyne
Claratyne Cold
Claratyne Decongestant
Clarinase
Clarinase Reperabs
Claritin
Claritin (TN)
Claritin D
Claritin Hives Relief
Claritin Hives Relief Reditab
Claritin reditab
Claritin Reditabs
Claritine
Clarityn
Clarityne
Clarityne Dy Repetabs
Clarityne-D
Clarium
CPD000058255
Cronopen
D00364
D017336
DB00455
DivK1c_000792
Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate
ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate
EU-0100680
Flonidan
Fristamin
Histaloran
HMS2051G11
HMS2090O18
HMS2093I15
HMS502H14
HSDB 3578
I14-0747
IDI1_000792
KBio1_000792
KBio2_001976
KBio2_004544
KBio2_007112
KBio3_001520
KBioGR_000693
KBioSS_001976
Klaritin
L 9664
L000667
L0223
L9664_SIGMA
Lergy
Lertamine
|
Lesidas
Lisino
Lopac0_000680
Lopac-L-9664
Loracert
Loradex
Loradif
Loranox
Lorantis
Lorastine
Loratadina
Loratadina [Spanish]
loratadine
Loratadine
Loratadine (JAN/USAN/INN)
Loratadine [USAN:BAN:INN]
Loratadine Redidose
Loratadine wyeth brand
Loratadine Wyeth Brand
Loratadinum
Loratadinum [Latin]
Loratidine
Loratyne
Loraver
Lorfast
Loritine
Lowadina
LS-114660
MLS000069647
MLS000758260
MLS001148466
MolPort-002-507-846
NCGC00015619-01
NCGC00015619-02
NCGC00015619-06
NCGC00015619-10
NCGC00023125-02
NCGC00023125-04
NCGC00023125-05
NCGC00023125-06
NCGC00023125-07
NCI60_041473
NINDS_000792
NSC721075
Nularef
Oprea1_027965
Optimin
Polaratyne
Pylor
Restamine
Rhinase
Rinomex
Roletra
S1358_Selleck
SAM001246987
Sanelor
Sch 29851
Sch29851
Sch-29851
Sensibit
Sinhistan Dy
SMR000058255
Sohotin
SPBio_001548
Spectrum_001496
SPECTRUM1503712
Spectrum2_001584
Spectrum3_000740
Spectrum4_000177
Spectrum5_001650
STK574925
Tadine
Talorat Dy
TL8005389
Tocris-1944
UNII-7AJO3BO7QN
Velodan
Versal
Wyeth brand OF loratadine
Wyeth Brand of Loratadine
Zeos
ZINC00537931
|
|
4 |
|
Tranexamic Acid |
Approved |
Phase 4 |
|
1197-18-8 |
5526 |
Synonyms:
08455_FLUKA
1197-17-7
1197-18-8
1ceb
3-14-00-00868 (Beilstein Handbook Reference)
4-(aminomethyl)cyclohexane-1-carboxylic acid
4-(Aminomethyl)cyclohexanecarboxylic acid
4-(Aminomethyl)-Cyclohexanecarboxylic Acid
857653_ALDRICH
A0236
AB00052260
AB1003647
AC1L1KJH
AC1Q50F3
AC1Q546D
AC1Q5U04
AC-4687
Acide tranexamique
Acide tranéxamique
Acide tranexamique [INN-French]
Acido tranexamico
ácido tranexámico
Acido tranexamico [INN-Spanish]
Acidum tranexamicum
Acidum tranexamicum [INN-Latin]
ALBB-006013
AMCA
AMCHA
AMH
Amikapron
Amstat
Anvitoff
AR-1F6595
BAY 3517
BPBio1_000069
BRN 2207452
BSPBio_000061
BSPBio_002837
Carxamin
CAS-1197-18-8
CHEBI:48669
CHEMBL292500
CHEMBL877
CID5526
cis-4-(Aminomethyl)cyclohexanecarboxylic acid
cis-4-Aminomethylcyclohexane-1-carboxylic acid
cis-AMCHA
CL 65336
CL-65336
Cyclocapron
Cyklokapron
Cyklokapron (TN)
D01136
DB00302
DivK1c_000655
DV 79
DV79
DV-79
EINECS 214-818-2
Emorhalt
Exacyl
Frenolyse
Hexapromin
Hexatron
HMS1568D03
HMS1921F08
HMS2092P03
HMS502A17
I04-0993
IDI1_000655
KABI 2161
KBio1_000655
KBio2_001871
KBio2_004439
KBio2_007007
KBio3_002337
KBioGR_000511
KBioSS_001871
|
LS-56611
LS-56612
LT00159441
Mastop
MolPort-001-792-390
MolPort-002-512-008
NCGC00016569-01
NCGC00016569-02
NCGC00016569-03
NCGC00094944-01
NCGC00094944-02
NINDS_000655
NSC 291305
NSC291305
Oprea1_786414
Prestwick_476
Prestwick0_000171
Prestwick1_000171
Prestwick2_000171
Prestwick3_000171
Rikavarin
Rikavarin (TN)
Rikavarin-S
RP 18,429
SPBio_000689
SPBio_001982
Spectrum_001391
SPECTRUM1502026
Spectrum2_000655
Spectrum3_001189
Spectrum4_000046
Spectrum5_001258
Spiramin
STK503668
STOCK1N-16183
t-AMCHA
Tamcha
Tranex
Tranexamate
tranexamic acid
Tranexamic acid
Tranexamic acid (JP15/USAN/INN)
Tranexamic acid [USAN:INN:BAN:JAN]
Tranexamic acid cis-form
Tranexamsaeure
Tranexan
Tranexmate
tranexmic acid
Tranexmic acid
Tranhexamate
Tranhexamic acid
trans AMCHA
Trans AMCHA
Trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid
trans-1-Aminomethylcyclohexane-4-carboxylic acid
Trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid
trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid
trans-4-(Aminomethyl)cyclohexanecarboxylate
trans-4-(Aminomethyl)cyclohexanecarboxylic acid
trans-4-(Aminomethyl)cyclohexane-carboxylic acid
trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester
trans-4-AMINOMETHYLCYCLOHEXANE-1-carboxylate
trans-4-aminomethylcyclohexane-1-carboxylic acid
trans-4-Aminomethylcyclohexane-1-carboxylic acid
trans-4-AMINOMETHYLCYCLOHEXANE-1-carboxylIC ACID
trans-Amcha
Transamin
Transamin (TN)
Transamlon
Trans-p-(Aminomethyl)cyclohexanecarboxylic
trans-p-(Aminomethyl)cyclohexanecarboxylic acid
trans-Tranexamate
trans-Tranexamic acid
Trasamlon
Ugurol
UNII-6T84R30KC1
WLN: L6TJ AVQ D1Z -T
|
|
5 |
|
Histamine |
Approved, Investigational |
Phase 4 |
|
51-45-6, 75614-87-8 |
774 |
Synonyms:
.beta.-Imidazolyl-4-ethylamine
[3H]histamine
1avn
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1qft
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-imidazolyl)ethylamine
2-(4-Imidazolyl)ethylamine
2-[4-Imidazolyl]ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-imidazoleethylamine
4-Imidazoleethylamine
51-45-6
53290_FLUKA
5-imidazoleethylamine
5-Imidazoleethylamine
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
beta-aminoethylglyoxaline
beta-Aminoethylglyoxaline
beta-aminoethylimidazole
beta-Aminoethylimidazole
beta-aminothethylglyoxaline
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
bmse000744
BSPBio_001117
BSPBio_002124
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
histamine
|
Histamine
Histamine (DCF)
Histamine [USAN]
Histamine Base
Histamine, Free Base
Histaminum
Histaminum (TN)
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L000292
L-histamine
Lopac0_000595
Lopac-H-7250
LS-75835
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
nchembio.87-comp54
nchembio714-comp1
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
Spectrum_000845
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
ST073926
STK346752
STOCK5S-55669
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
β-Imidazolyl-4-ethylamine
|
|
6 |
|
Cetirizine |
Approved |
Phase 4 |
|
83881-51-0 |
2678 |
Synonyms:
(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid
(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
(2-{4-[(4-Chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-ethoxy)-acetic acid
[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid
2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
83881-51-0
83881-52-1 (di-hydrochloride)
AC1L1E7T
AC1Q768B
AC-5545
AKOS003589059
Alerlisin
Aliud brand OF cetirizine dihydrochloride
Alpharma brand OF cetirizine dihydrochloride
AWD.pharma brand OF cetirizine dihydrochloride
Azupharma brand OF cetirizine dihydrochloride
Basics brand OF cetirizine dihydrochloride
Benaday
BPBio1_000469
BRD-A42571354-300-05-4
BSPBio_000425
BSPBio_002302
C07778
C21H25ClN2O3
Cetalerg
Ceterifug
Ceti tad
Cetiderm
Cetiderm (TN)
Cetidura
Cetil von CT
CetiLich
Ceti-puren
Cetirigamma
Cetirizin
Cetirizin al
Cetirizin azu
Cetirizin basics
Cetirizina
Cetirizina [Spanish]
cetirizine
Cetirizine
Cetirizine (INN)
Cetirizine [INN:BAN]
Cetirizine dihydrochloride
Cetirizine hydrochloride
Cetirizinum
Cetirizinum [Latin]
Cetirlan
Cetrizine Hcl
Cetryn
CHEBI:3561
CHEMBL1000
CID2678
CPD001453715
|
CT-Arzneimittel brand OF cetirizine dihydrochloride
D07662
DB00341
Dermapharm brand OF cetirizine dihydrochloride
Dihydrochloride, cetirizine
Glaxo wellcome brand OF cetirizine dihydrochloride
Hitrizin Film Tablet
HMS1539O07
Humex
I06-0454
Krewel brand OF cetirizine dihydrochloride
L000655
Lacer brand OF cetirizine dihydrochloride
Lichtenstein brand OF cetirizine dihydrochloride
LS-11409
Menarini brand OF cetirizine dihydrochloride
Merck dura brand OF cetirizine dihydrochloride
MLS002222268
MolPort-002-506-309
NCGC00167781-01
NCGC00167781-02
NCGC00167781-03
NCGC00167781-04
nchembio714-comp3
P-071
Pfizer brand OF cetirizine dihydrochloride
Pfizer consumer healthcare brand OF cetirizine dihydrochloride
Prestwick0_000503
Prestwick1_000503
Prestwick2_000503
Prestwick3_000503
Reactine
Rodleben brand OF cetirizine
SAM002589989
Sanofi synthelabo brand OF cetirizine dihydrochloride
Setir
SMR000145214
SPBio_002346
STK711108
STOCK2S-03020
TAD brand OF cetirizine dihydrochloride
TimTec1_002075
UCB brand OF cetirizine dihydrochloride
UCB pharma brand OF cetirizine dihydrochloride
UNII-YO7261ME24
United drug brand OF cetirizine dihydrochloride
Virlix
Voltric
Wolff brand OF cetirizine dihydrochloride
Wörwag brand OF cetirizine dihydrochloride
Zetir
Ziptek
Zirtek
Zyrlex
Zyrtec
|
|
7 |
|
Desloratadine |
Approved, Investigational |
Phase 4 |
|
100643-71-8 |
124087 |
Synonyms:
100643-71-8
8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
AC-1279
AC1L3XUD
Aerius
AKOS000280921
Allex
Azomyr
BB_SC-2104
C121345
CHEBI:291342
CHEMBL1172
CID124087
Claramax
Clarinex
Clarinex (TN)
Clarinex Reditabs
Clarinex RediTabs
CPD000149358
D03693
D3787
DB00967
Denosin
Desalex
Descarboethoxyloratadine
Descarboethoxyloratadine acetate
Descarboethoxyoratidine
Desloratadina
desloratadine
|
Desloratadine
Desloratadine (USAN/INN)
Desloratadine [USAN]
Desloratidine
Essex brand of desloratadine
HMS2052H05
HMS2090C06
HMS2093F19
I06-1866
L001025
LS-181814
MLS000559042
MLS000759406
MLS001201801
MolPort-000-883-875
NCGC00159325-02
NCGC00159325-03
NCGC00159325-04
Neoclarityn
NeoClarityn
NSC675447
Opulis
SAM001246545
Sch 34117
Sch-34117
Schering brand of desloratadine
Schering-Plough brand of desloratadine
SMR000149358
STK586537
TL8000065
UNII-FVF865388R
|
|
8 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
9 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
10 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
11 |
|
Immunoglobulins |
|
Phase 4 |
|
|
|
12 |
|
Antibodies |
|
Phase 4 |
|
|
|
13 |
|
Antibodies, Monoclonal |
|
Phase 4 |
|
|
|
14 |
|
Immunoglobulin E |
|
Phase 4 |
|
|
|
15 |
|
Immunoglobulins, Intravenous |
|
Phase 4 |
|
|
|
16 |
|
Hemostatics |
|
Phase 4 |
|
|
|
17 |
|
Coagulants |
|
Phase 4 |
|
|
|
18 |
|
Antifibrinolytic Agents |
|
Phase 4 |
|
|
|
19 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
20 |
|
Histamine Antagonists |
|
Phase 4 |
|
|
|
21 |
|
Histamine H1 Antagonists |
|
Phase 4 |
|
|
|
22 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
23 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
24 |
|
Histamine Phosphate |
|
Phase 4 |
|
51-74-1 |
65513 |
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
|
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
LS-78569
UNII-QWB37T4WZZ
|
|
25 |
|
Histamine H1 Antagonists, Non-Sedating |
|
Phase 4 |
|
|
|
26 |
|
Cholinergic Antagonists |
|
Phase 4 |
|
|
|
27 |
|
Methotrexate |
Approved |
Phase 3 |
|
1959-05-2, 59-05-2 |
126941 |
Synonyms:
4-Amino-10-methylfolate
4-amino-10-methylfolic acid
4-Amino-10-methylfolic acid
4-Amino-N(10)-methylpteroylglutamate
4-amino-N(10)-methylpteroylglutamic acid
4-Amino-N(10)-methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Dicesium salt methotrexate
Emtexate
Emtexic acid
Folex
HDMTX
Hydrate, methotrexate
L-Amethopterin
Ledertrexate
Ledertrexic acid
Metatrexan
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate
|
Méthotrexate
Methotrexate hydrate
Methotrexate sodium
Methotrexate Sodium
Methotrexate, (D)-isomer
Methotrexate, (DL)-isomer
Methotrexate, dicesium salt
Methotrexate, disodium salt
Methotrexate, sodium salt
Methotrexatum
Methotrexic acid
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
MTX
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamate
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-Bismethylpteroylglutamic acid
N-Bismethylpteroylglutamic Acid
Otrexup
Rheumatrex
Sodium, methotrexate
Trexall
Xatmep
|
|
28 |
|
Levoleucovorin |
Approved, Investigational |
Phase 3 |
|
68538-85-2 |
149436 |
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-Formyltetrahydrofolate
(6S)-5-formyltetrahydrofolic acid
(6S)-5-Formyltetrahydrofolic acid
(6S)-Folinate
(6S)-Folinic acid
(6S)-Leucovorin
(S)-Leucovorin
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
6 S Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
ácido levofolínico
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid SF
Folinic acid-SF
Fusilev
Kunyrin
Leucoverin
|
Leucovorin
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leukovorin
Leukovorum
Levo leucovorin
Levofolene
Levofolinate
Levofolinic acid
Levoleucovorin
Levo-leucovorin
L-Folinate
L-Folinic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
29 |
|
Levocetirizine |
Approved |
Phase 3 |
|
130018-77-8 |
1549000 |
Synonyms:
(-)-Cetirizine
(2-(4-((R)-p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid
(R)-Cetirizine
2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
Levocetirizina
Levocetirizine
|
Levocetirizine dihydrochloride
Levocetrizine
Xazal
Xusal
Xyzal
|
|
30 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl PABA
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
31 |
|
Diphenhydramine |
Approved, Investigational |
Phase 3 |
|
147-24-0, 58-73-1 |
3100 |
Synonyms:
147-24-0
147-24-0 (HYDROCHLORIDE)
2-(benzhydryloxy)-N,N-dimethylethylamine
2-(Benzhydryloxy)-N,N-dimethylethylamine
2-(Benzhydryloxy)-N,N-dimethylethylamine, hydrochloride
2-(diphenylmethoxy)-N,N-dimethylethanamine
2-(Diphenylmethoxy)-N,N-dimethylethylamine
2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine
2-benzhydryloxyethyl-N,N-dimethylammonium
2-benzhydryloxy-N,N-dimethylethanamine
2-diphenylmethoxy-N,N-demthylethanamine
2-Diphenylmethoxy-N,N-demthylethanamine
2-Diphenylmethoxy-N,N-dimethylethylamine
2PM
58-73-1
88637-37-0 (citrate (1:1))
a-(2-Dimethylaminoethoxy)diphenylmethane
AB00053460
AC-13704
AC1L1F65
AKOS003658554
Aleryl
Alledryl
Allerdryl
Allergan
Allergan B
Allergeval
Allergical
Allergina
Allergival
Allermax Caplets
Aller-Med
alpha-(2-Dimethylaminoethoxy)diphenylmethane
Amidryl
Antistominum
Antitussive
Antomin
Automin
Bagodryl
Banophen
Banophen Caplets
Baramine
b-Dimethylaminoethanol diphenylmethyl ether
b-Dimethylaminoethyl benzhydryl ether
Beldin
Belix
Bena
Benachlor
Benadrin
Benadryl
Benadryl (hydrochloride)
Benadryl Allergy
BENADRYL HCl
Ben-allergin
Benapon
Bendylate
Benhydramin
Benodin
Benodine
Benylan
Benylin
Benzantin
Benzantine
Benzhydramine
Benzhydraminum
Benzhydril
Benzhydroamina
Benzhydryl
beta-Dimethylamino-aethyl-benzhydryl-aether
beta-Dimethylamino-aethyl-benzhydryl-aether [German]
beta-Dimethylaminoethanol diphenylmethyl ether
beta-dimethylaminoethyl benzhydryl ether
beta-Dimethylaminoethyl benzhydryl ether
beta-Dimethylaminoethylbenzhydrylether
Betramin
BIDD:GT0152
BPBio1_000275
BRD-K47278471-003-05-7
BRN 1914136
BSPBio_000249
BSPBio_002219
CAS-147-24-0
CCRIS 1959
CHEBI:127629
CHEBI:4636
CHEMBL657
CID3100
Citrate, diphenhydramine
Compoz
CPD-10890
D00300
Dabylen
DB01075
DB06975
Debendrin
Dermistina
Dermodrin
Desentol
Diabenyl
Diabylen
Dibendrin
Dibenil
Dibondrin
Difedryl
Difenhidramina
Difenhidramina [INN-Spanish]
Difenhydramin
Difenhydramine
Difenidramina
Difenidramina [Italian]
Dihidral
Dimedrol
Dimedrol base
Dimedrolum
Dimedryl
Dimehydrinate
Dimethylamine benzhydryl ester
|
Diphamine
Diphantine
Diphen
Diphen Cough
Diphenhist
Diphenhist Captabs
diphenhydramine
Diphenhydramine
Diphenhydramine (JP15/INN)
Diphenhydramine [INN:BAN:JAN]
Diphenhydramine Base
Diphenhydramine citrate
Diphenhydramine citrate (1:1)
Diphenhydramine HCl
Diphenhydramine hydrochloride
DIPHENHYDRAMINE, ANTISTOMINUM, BENZHYDRAMINE
Diphenhydraminum
Diphenhydraminum [INN-Latin]
Diphenylhydramin
Diphenylhydramine
DivK1c_000368
Dobacen
Dormarex 2
Dormin
Dryistan
Drylistan
Dylamon
EINECS 200-396-7
Etanautine
FAR 90X2
Genahist
Histaxin
HMS2089E06
HSDB 3066
Hyadrine
Hydramine
Hydrochloride, diphenhydramine
Hyrexin
I14-6749
Ibiodral
IDI1_000368
KBio1_000368
KBio2_001460
KBio2_004028
KBio2_006596
KBio3_001439
KBioGR_001099
KBioSS_001460
L000227
Lopac0_000377
Lopac-D-3630
LS-68208
Medidryl
Mephadryl
MLS002222276
MolPort-001-783-508
N-(2-(diphenylmethoxy)ethyl)-N,N-dimethylamine
N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine
N-(Benzhydryloksy-etylo)dwumetyloamina
N-(Benzhydryloksy-etylo)dwumetyloamina [Polish]
N,N-Dimethyl-2-(diphenylmethoxy)-ethylamine hydrochloride
N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE
Nausen
NCGC00015335-01
NCGC00015335-02
NCGC00015335-03
NCGC00015335-10
NCGC00024414-03
NCGC00024414-04
nchembio747-comp18
NCI60_002916
NCI60_022782
Nervine Nighttime Sleep-Aid
NINDS_000368
Novamina
NSC665800
Nytol Quickcaps
Nytol Quickgels
O-benzhydryldimethylaminoethanol
O-Benzhydryldimethylaminoethanol
Oprea1_254625
PM 255
Prestwick0_000065
Prestwick1_000065
Prestwick2_000065
Prestwick3_000065
Probedryl
Restamin
Restamin (TN)
Rigidil
S51
Siladryl
Silphen
Sleep-Eze D
Sleep-Eze D Extra Strength
SMR001307259
SPBio_000961
SPBio_002170
Spectrum_000980
Spectrum2_000961
Spectrum3_000400
Spectrum4_000520
Spectrum5_000915
STK103720
STOCK2S-94461
Syntedril
Syntodril
TL8003758
Twilite Caplets
UNII-8GTS82S83M
Unisom Sleepgels Maximum Strength
α-(2-dimethylaminoethoxy)diphenylmethane
Α-(2-dimethylaminoethoxy)diphenylmethane
β-dimethylaminoethanol diphenylmethyl ether
Î’-dimethylaminoethanol diphenylmethyl ether
β-dimethylaminoethyl benzhydryl ether
Î’-dimethylaminoethyl benzhydryl ether
|
|
32 |
|
tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
|
Synonyms:
ácido tánico
Gallotannic acid
|
|
|
33 |
|
Promethazine |
Approved, Investigational |
Phase 3 |
|
60-87-7 |
4927 |
Synonyms:
(2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine
(2-Dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine
(Dimethylamino-2-propyl-10-phenothiazine hydrochloride
10-(2-(Dimethylamino)-2-methylethyl)phenothiazine
10-(2-(Dimethylamino)propyl)phenothiazine
10-(2-Dimethylaminopropyl)phenothiazine
10-[2-(dimethylamino)propyl]phenothiazine
10-[2-(Dimethylamino)propyl]phenothiazine
10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl- (9CI)
10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl-, radical ion(1+)
3277 RP
3389 R.p.
38878-40-9
4182 R.p.
4-27-00-01253 (Beilstein Handbook Reference)
60-87-7
73745-50-3
A-91033
AB00053535
AC-15939
AC1L1J92
Antiallersin
Aprobit
Atosil
Avomine
BPBio1_000744
BRN 0088554
BSPBio_000676
BSPBio_002777
C07404
Camergan
CCRIS 7056
CHEBI:8461
CHEMBL643
CID4927
D00494
DB01069
Dimapp
Dimethylamino-isopropyl-phenthiazin
Dimethylamino-isopropyl-phenthiazin [German]
Diphergan
Diprazin
Diprazine
Diprozin
DivK1c_000005
EINECS 200-489-2
Fargan
Fenazil
Fenetazina
Fenetazine
Genphen
Hiberna
Histargan
HMS2089E08
HSDB 3173
Hydrochloride, promethazine
IDI1_000005
Iergigan
InChI=1/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3
Isophenergan
Isopromethazine
KBio1_000005
KBio2_001348
KBio2_003916
KBio2_006484
KBio3_001997
KBioGR_001697
KBioSS_001348
L000495
Lercigan
Lergigan
Lilly 01516
Lilly 1516
Lopac0_000899
LS-264
Metaryl
MolPort-001-783-684
N-(2'-dimethylamino-2'-methyl)ethylphenothiazine
N-(2'-Dimethylamino-2'-methyl)ethylphenothiazine
N,N,alpha-trimethyl-10H-phenothiazine-10-ethanamine
N,N,alpha-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,a-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,α-trimethyl-10H-phenothiazine-10-ethanamine
N,N,Α-trimethyl-10H-phenothiazine-10-ethanamine
N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine
|
N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine
N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine hydrochloride
NCGC00015817-10
NCGC00089735-02
NCGC00089735-03
NCI60_001878
NCI-C60673
N-Dimethylamino-2-methylethyl thiodiphenylamine
NINDS_000005
NSC 30321
NSC30321
Oprea1_758749
Pelpica
Phargan
Phenargan
Phenergan
Phenerzine
Phenoject-50
Phensedyl
Pilothia
Pilpophen
Pipolfen
Pipolphen
Pipolphene
Prestwick0_000888
Prestwick1_000888
Prestwick2_000888
Prestwick3_000888
Pro-50
Proazaimine
Proazamine
Procit
Promacot
Promazinamide
Promergan
Promesan
Promet
Prometasin
Prometazin
Prometazina
Prometazina [INN-Spanish]
Prometazine
Prometh
Promethacon
Promethaine
Promethazin
promethazine
Promethazine
Promethazine (JAN/INN)
PROMETHAZINE (SEE ALSO PROMETHAZINE HYDROCHLORIDE 58-33-3)
Promethazine [INN:BAN]
Promethazine hydrochloride
PromethazineHcl
Promethazinum
Promethazinum [INN-Latin]
Promethegan
Promethiazine
Promezathine
Prorex
Protazine
Prothazin
Prothazine
Provigan
Pyrethia
Pyrethiazine
Remsed
Romergan
RP 3277
Rumergan
SKF 1498
SPBio_000799
SPBio_002895
Spectrum_000868
Spectrum2_000840
Spectrum3_001019
Spectrum4_001149
Spectrum5_000977
Tanidil
Thiergan
UNII-FF28EJQ494
Valergine
Vallergine
WLN: T C666 BN ISJ B1Y1&N1&1
WY 509
Zipan-25
|
|
34 |
|
Cyproheptadine |
Approved |
Phase 3 |
|
129-03-3 |
2913 |
Synonyms:
129-03-3
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,D)cycloheptenylidene)piperidine
4-(5-dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene
4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
41354-29-4
4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine
5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,D)cyclopheptene
5-20-08-00500 (Beilstein Handbook Reference)
AC1L1ER8
AKOS004119847
Antergan
BIDD:GT0324
Biomol-NT_000131
BPBio1_000096
BPBio1_000155
BRD-K28143534-001-01-4
BRD-K28143534-003-03-6
BRN 1685976
BSPBio_000086
C06935
CAS-969-33-5
CCRIS 5232
CHEBI:4046
CHEMBL516
CID2913
Ciproheptadina
Ciproheptadina [INN-Spanish]
Ciprovit
Ciprovit (TN)
Cypoheptadine
Cyproheptadiene
Cyproheptadin
Cyproheptadine
|
CYPROHEPTADINE
Cyproheptadine (INN)
Cyproheptadine [INN:BAN]
Cyproheptadine Hcl
Cyproheptadinum
Cyproheptadinum [INN-Latin]
D07765
DB00434
Dibenzosuberonone/Cyproheptadine
Dihexazin
Dronactin
EINECS 204-928-9
Eiproheptadine
HMS2090P20
HSDB 3048
L001016
Lopac0_000246
Lopac-C-6022
LS-114933
MK 141
MolPort-002-507-777
NCGC00015252-01
NCGC00015252-02
NCGC00015252-03
NCGC00015252-09
NCGC00024293-02
NCGC00024293-04
NCGC00024293-05
nchembio.559-comp10
Oprea1_498140
PDSP1_001229
PDSP2_001213
Periactin
Periactine
Periactinol
Peritol
Prestwick0_000103
Prestwick1_000103
Prestwick2_000103
Prestwick3_000103
SPBio_002025
STK802098
Tocris-0996
UNII-2YHB6175DO
Viternum
|
|
35 |
|
Vitamin D3 |
Approved, Nutraceutical |
Phase 3 |
|
67-97-0 |
6221 5280795 |
Synonyms:
()-Vitamin D3
(+)-vitamin D3
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3Î’,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
47763_SUPELCO
57651-82-8
67-97-0
7-DEHYDROCHOLESTEROL
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
ACTIVATED
Activated 7-dehydrocholesterol
Arachitol
Bio-0845
bmse000507
BPBio1_000460
BSPBio_000418
BSPBio_002408
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
Calciol
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
cholecalciferol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferols
Cholecalciferolum
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
|
CID7067440
CID7251172
CID7251174
CID9821465
Colecalciferol
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Dihydrocholesterol
DivK1c_006276
Duphafral D3 1000
Ebivit
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
FeraCol
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC375571
NSC-375571
Oleovitamin D3
Prestwick_63
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Provitamine
Provitina
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SpecPlus_000180
Spectrum_001163
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
SR-05000001559
SR-05000001559-3
ST057172
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
Vi-de-3-hydrosol
Vigorsan
VITAMIN D
Vitamin D 3
vitamin d-3
Vitamin D3
Vitamin D-3
Vitamin D3 emulsifiable
VITAMIN D3 POWDER
VITAMIN_D3
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
δ-D
|
|
36 |
|
Ergocalciferol |
Approved, Nutraceutical |
Phase 3 |
|
50-14-6 |
5280793 |
Synonyms:
(+)-Vitamin D2
(3b,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3Î’,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,secoergosta-5,7,10(19)-ol
31316-19-5
47768_SUPELCO
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3ah)-indanylidene]ethylidene]-cyclohexanol
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
beta-Ol
bmse000510
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
Calciferols
Calciferolum
Calciferon 2
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
component of Geltabs Vitamin D
Condacaps
Condocaps
Condol
Crtron
Crystallina
D00187
D2, Vitamin
Daral
D-Arthin
Davitamon D
Davitin
DB00153
Decaps
Dee-osterol
Dee-Osterol
Dee-ron
Dee-Ron
Dee-ronal
Dee-Ronal
Dee-roual
Dee-Roual
delta-Arthin
Deltalin
delta-Tracetten
De-rat concentrate
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
D-Tracetten
E5750_SIGMA
EINECS 200-014-9
Ercalciol
ergocalciferol
|
Ergocalciferol
Ergocalciférol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
'Ergosterol irradiated'
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
Haliver
Hi-deratol
Hi-Deratol
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
Metadee
Mina D2
MLS001332467
MLS001332468
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
Novovitamin-D
NSC 62792
NSC62792
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick_554
Prestwick3_000420
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
Shock-ferol
Shock-ferol sterogyl
SMR000857106
Sorex C.R
Sorex C.R.
SPECTRUM1500276
Spectrum5_000666
ST057150
Sterogyl
STOCK1N-53397
Synthetic vitamin D
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in oil
Viosterol in Oil
Vitamin D 2
vitamin d-2
Vitamin D2
Vitamin- D2
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
Vitamin-?D2
VITAMIN_D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
|
|
37 |
|
Vitamin D |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
1406-16-2 |
|
Synonyms:
|
Vitamin D, unspecified form
|
|
38 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
ácido fólico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
|
Folipac
Folsaeure
Folsan
Folsaure
Folsäure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-pteroyl-L-glutamic acid
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
39 |
|
Trace Elements |
|
Phase 3 |
|
|
|
40 |
|
Vitamin D2 |
|
Phase 3 |
|
|
|
41 |
|
Ergocalciferols |
|
Phase 3 |
|
|
|
42 |
|
Vitamins |
|
Phase 3 |
|
|
|
43 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
44 |
|
Calciferol |
|
Phase 3 |
|
|
|
45 |
|
Nutrients |
|
Phase 3 |
|
|
|
46 |
|
Micronutrients |
|
Phase 3 |
|
|
|
47 |
|
Folic Acid Antagonists |
|
Phase 3 |
|
|
|
48 |
|
Vitamin B Complex |
|
Phase 3 |
|
|
|
49 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
50 |
|
Vitamin B9 |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 73)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of Desloratadine 5mg (Denosin®) With Levocetirizine 5mg (Xyzal®) in the Treatment of Chronic Idiopathic Urticaria Patients |
Unknown status |
NCT00346606 |
Phase 4 |
Denosin® and Xyzal® |
2 |
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria |
Completed |
NCT02392624 |
Phase 4 |
Omalizumab;Placebo |
3 |
A Phase IV, Multicenter, Single-arm and Open-label Study With Omalizumab (Xolair®) in Chronic Spontaneous Urticaria (CSU) Patients Who Remain Symptomatic Despite Antihistamine (H1) Treatment |
Completed |
NCT02550106 |
Phase 4 |
OMALIZUMAB |
4 |
A Comparative Study on Clinical Efficacy and Safety of Levocetirizine 5 mg Oral Capsules Once Daily in the Morning vs. Desloratadine 5 mg Oral Capsules Once Daily in the Morning in Patients Suffering From Chronic Idiopathic Urticaria (CIU) |
Completed |
NCT00264303 |
Phase 4 |
Levocetirizine;Desloratadine |
5 |
A Study of the Efficacy, Safety, and Quality of Life (QOL) in Patients With Chronic Idiopathic Urticaria Dosed With AERIUS Tablets (Desloratadine 5 mg, 10 mg, or 20 mg Once Daily) |
Completed |
NCT00536380 |
Phase 4 |
5-mg Desloratadine;10-mg Desloratadine;20-mg Desloratadine |
6 |
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monocloncal Antibody |
Completed |
NCT03183024 |
Phase 4 |
|
7 |
A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU) |
Completed |
NCT00751218 |
Phase 4 |
desloratadine;placebo;cetirizine |
8 |
An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria |
Completed |
NCT00795522 |
Phase 4 |
Desloratadine |
9 |
Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria |
Completed |
NCT03111628 |
Phase 4 |
Omalizumab |
10 |
Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria |
Completed |
NCT01701583 |
Phase 4 |
Omalizumab |
11 |
A Pilot, Multicenter, Double-blind Randomized Study for Comparison of Aerius® "Continuous Treatment" Versus Aerius® "PRN Regimen" on Chronic Idiopathic Urticaria Patient Quality of Life |
Completed |
NCT00783354 |
Phase 4 |
desloratadine;desloratadine |
12 |
Efficacy and Safety of Levocetirizine Alone or in Combination With Tranexamic Acid in the Treatment of Spontaneous Chronic Urticaria. Multicentric Controlled Randomized Study in Cross-over, Double-blind |
Recruiting |
NCT03789422 |
Phase 4 |
association of levocetirizine and tranexamic acid;Levocetirizine only |
13 |
A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU) |
Terminated |
NCT00751166 |
Phase 4 |
Desloratadine;Cetirizine;placebo |
14 |
High Dose Vitamin D Supplementation in Treatment of Chronic Spontaneous Urticaria |
Unknown status |
NCT02873364 |
Phase 3 |
Vitamin D3 (High dose);Vitamin D3 (Low dose) |
15 |
Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria |
Unknown status |
NCT02166151 |
Phase 3 |
Omalizimab |
16 |
A Phase III, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine Treatment (H1) |
Completed |
NCT01292473 |
Phase 3 |
Placebo;Omalizumab |
17 |
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) |
Completed |
NCT01287117 |
Phase 3 |
Omalizumab;Placebo |
18 |
OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in CSU Patients |
Completed |
NCT02161562 |
Phase 3 |
omalizumab;omalizumab |
19 |
A Randomized, Double-blind, Placebo-controlled, 28-week Treatment With a 8 Week Follow-up to Investigate the Impact of Omalizumab on Quality of Life Measures and the Incidence and Severity of Angioedema Despite H1-antihistamine Therapy. |
Completed |
NCT01723072 |
Phase 3 |
Placebo |
20 |
Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria Resistant to the Licensed Dosage |
Completed |
NCT02372604 |
Phase 3 |
Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.;Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration. |
21 |
A Phase III Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment |
Completed |
NCT03328897 |
Phase 3 |
Omalizumab;Placebo |
22 |
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite H1 Antihistamine Therapy |
Completed |
NCT02329223 |
Phase 3 |
|
23 |
Phase 3 Study, Exploratory, Disease Activity Controlled Dose Escalating Study to Assess the Efficacy, and Safety of Treatment With Bilastine 20 mg, 40 mg and 80 mg in Chronic Spontaneous Urticaria. |
Completed |
NCT02213367 |
Phase 3 |
Bilastine;Bilastine;Bilastin |
24 |
Multiple-Dose Safety and Tolerance Study of Desloratadine in Atopic Pediatric Subjects and Pediatric Subjects With Chronic Idiopathic Urticaria, Ages >=2 to <12 Years, Who Are Poor Metabolizers of Desloratadine |
Completed |
NCT00757562 |
Phase 3 |
desloratadine;Placebo |
25 |
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists |
Completed |
NCT01264939 |
Phase 3 |
Omalizumab;Placebo;H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist;Diphenhydramine |
26 |
Randomized Clinical Trial Evaluating the Efficacy of Methotrexate in Addition to Anti-H1 Versus Placebo and Anti-H1 in the Treatment of Severe Chronic Idiopathic Urticaria |
Completed |
NCT01960283 |
Phase 3 |
Methotrexate (Novatrex ®) + anti-H1;Placebo + anti-H1 |
27 |
Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria |
Completed |
NCT00421109 |
Phase 3 |
Bilastine;Levocetirizine;Placebo |
28 |
A Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Chronic Idiopathic Urticaria (CIU) |
Completed |
NCT00525382 |
Phase 3 |
levocetirizine dihydrochloride |
29 |
A Multi-center, Double-blinded and Open-label Extension Study to Evaluate the Efficacy and Safety of Ligelizumab as Retreatment, Self-administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301 |
Recruiting |
NCT04210843 |
Phase 3 |
Ligelizumab |
30 |
A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines |
Recruiting |
NCT03580369 |
Phase 3 |
|
31 |
A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines |
Recruiting |
NCT03580356 |
Phase 3 |
|
32 |
A Multi-center, Open-label Study to Investigate the Safety/Tolerability and Efficacy of Ligelizumab (QGE031) in the Treatment of Adult Japanese Patients With Chronic Spontaneous Urticaria (CSU) Inadequately Controlled With H1 Antihistamines |
Recruiting |
NCT03907878 |
Phase 3 |
|
33 |
Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naïve to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab |
Recruiting |
NCT04180488 |
Phase 3 |
Dupilumab SAR231893;Placebo;non sedating H1-antihistamine |
34 |
A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment |
Not yet recruiting |
NCT04426890 |
Phase 3 |
|
35 |
A Multi-center, Randomized, Double Blind, Dose Escalating Phase III Study on the Efficacy, Safety and Long Term Outcome of Continuous vs. on Demand Treatment of Chronic Spontaneous Urticaria With Rupatadine. |
Terminated |
NCT02358265 |
Phase 3 |
10 mg Rupatadine on demand;10 mg Rupatadine;20 mg Rupatadine;10 mg Rupatadine on demand (sham updosing to 20 mg) |
36 |
A 6-Week Multicentre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Rupatadine 10 and 20 Mg in the Treatment of Chronic Idiopathic Urticaria (CIU): a Phase III Clinical Trial |
Terminated |
NCT00199251 |
Phase 3 |
RUPATADINE |
37 |
A 6 Week Randomized, Double Blind, Placebo-controlled Study With a 6 Week Open Label Extension to Assess the Efficacy of Etanercept in the Treatment of Chronic Idiopathic Urticaria |
Withdrawn |
NCT01030120 |
Phase 2, Phase 3 |
etanercept;placebo |
38 |
A Phase II Randomized Double-Blind Placebo Controlled Single Center Study of Canakinumab Treatment of Adult Patients With Moderate to Severe Chronic Idiopathic Urticaria |
Unknown status |
NCT01635127 |
Phase 2 |
Canakinumab;Placebo |
39 |
An Open Label, Multicenter, Extension Study to Evaluate the Long-term Safety of QGE031 240 mg s.c. Given Every 4 Weeks for 52 Weeks in Chronic Spontaneous Urticaria Patients Who Completed Study CQGE031C2201 |
Completed |
NCT02649218 |
Phase 2 |
|
40 |
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU) |
Completed |
NCT02477332 |
Phase 2 |
|
41 |
A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria |
Completed |
NCT01987947 |
Phase 2 |
Placebo;Quilizumab |
42 |
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU). |
Completed |
NCT03137069 |
Phase 2 |
GDC-0853;Placebo |
43 |
A Phase IIa, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of the CRTh2 Antagonist AZD1981 in Patients With Chronic Idiopathic Urticaria (CIU) Who Are Refractory to H1 Antihistamines |
Completed |
NCT02031679 |
Phase 2 |
AZD1981;Placebo |
44 |
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) |
Completed |
NCT00866788 |
Phase 2 |
omalizumab;placebo;H1 antihistamines;Diphenhydramine |
45 |
A Phase II, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Determine the Mode of Action of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) |
Completed |
NCT01599637 |
Phase 2 |
IGE025;placebo |
46 |
A Phase 2b Multinational, Randomised, Double-blind, Parallel- Group, 24-week Placebo-controlled Study With 28-week Extension to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) |
Recruiting |
NCT04612725 |
Phase 2 |
|
47 |
An Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Eligible Subjects With CSU Who Have Participated in Preceding Studies With LOU064 |
Recruiting |
NCT04109313 |
Phase 2 |
LOU064 |
48 |
A Multicenter, Randomized, Double-blind, Placebo- Controlled Phase 2b Dose-finding Study to Investigate the Efficacy, Safety and Tolerability of LOU064 in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines |
Recruiting |
NCT03926611 |
Phase 2 |
LOU064 Arm 1;LOU064 Arm 2;LOU064 Arm 3;LOU064 Arm 4;LOU064 Arm 5;LOU064 Arm 6;Placebo arm |
49 |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Phase 2, 16-week Treatment Study With a 16 Week Follow-up Period to Assess the Efficacy and Safety of Dupilumab (Anti-IL4Ra) in Adult Patients With Chronic Spontaneous Urticaria Despite H1-antihistamine Treatment. |
Recruiting |
NCT03749135 |
Phase 2 |
Dupilumab;Placebo |
50 |
A Phase 2a Placebo-controlled, Open-label, Single Center Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients |
Recruiting |
NCT04439955 |
Phase 2 |
CBD |
|